Last reviewed · How we verify
Botox® (onabotulinumtoxinA)
OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | Botox® (onabotulinumtoxinA) |
|---|---|
| Also known as | Botox® (onabotulinumtoxinA)injection |
| Sponsor | Seoul National University Hospital |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | FDA-approved |
Mechanism of action
The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, leading to flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Overactive bladder
- Hyperhidrosis
- Glabellar lines and facial wrinkles (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Flu-like symptoms
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial (PHASE4)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox® (onabotulinumtoxinA) CI brief — competitive landscape report
- Botox® (onabotulinumtoxinA) updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI